IVF market Report, published by Allied Market Research, forecasts that the global market is expected to garner $21.6 billion by 2020, registering a CAGR of 11.6% during the period 2013-2020. Rising rate of infertility is the key factor driving the growth of the IVF market. In addition, rising awareness has led to increase in egg donation. For instance, in the U.S., the number of egg donation cycles has increased from 11,000 in the year 2000 to 18000 in 2010.
Medical tourism is providing an excellent opportunity for the growth of this market. The cost of IVF in New York is approximately around $10,000- $15,000 and the same costs up to $6000 in Thailand. Developing economies are emerging to be the most preferred destination for IVF treatments with increasing focus on advanced technologies, improving health care infrastructure and favourable health care cost. Globally, around 30 countries have some form of Assisted Reproductive Techniques (ART) with certain limitations. Few countries such as Israel, Belgium and France offer comprehensive reimbursement schemes.
Intra cytoplasmic sperm injection (ICSI) as a technique is promising significant opportunities. "ICSI has been successfully performed even in complex situations where there are multiple factors responsible for infertility among both male or/and female patients. Moreover, this has been best suitable for those who have had repeated failure through conventional IVF procedure." quote Debbie Shields and Rohini Patil.
However, major restraint in the IVF market is the cost factor. The total cost of the treatment depends on the number of cycles, cost of the procedure, drugs and hormones. The average cost of the IVF treatment is about $10,000- $20,000. Europe is expected to generate revenue of $8 billion by 2020 growing at a CAGR of 10.2% during 2013 to 2020. However, Asia-Pacific is a high-opportunity market that is expected to grow at a CAGR of 17.1% from 2013 to 2020.
The report has profiled some of the key players of the market such as Vitrolife AB, EMD Serono Inc, Irvine scientific, Cooper Surgical Inc, Cook Medical Inc, Thermo Fisher Scientific Inc, Genea Biomedx, Auxogyn, Inc, Oxford Gene Technology and Ovascience.